Health Care [ 3/12 ] | Biotechnology [ 12/75 ]
NASDAQ | Common Stock
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.
The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; CellectisS. A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.
The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.
Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 31, 25 | -0.18 Increased by +30.77% | -0.18 Decreased by -2.04% |
| Nov 6, 25 | -0.25 Increased by +10.71% | -0.26 Increased by +4.47% |
| Aug 7, 25 | -0.33 Increased by +2.94% | -0.28 Decreased by -17.86% |
| May 7, 25 | -0.36 Increased by +14.29% | -0.42 Increased by +14.29% |
| Feb 26, 25 | -0.26 Increased by +42.22% | -0.27 Increased by +2.84% |
| Nov 7, 24 | -0.28 Increased by +39.13% | -0.30 Increased by +6.67% |
| Aug 8, 24 | -0.34 Increased by +27.66% | -0.35 Increased by +2.86% |
| May 9, 24 | -0.42 Increased by +16.00% | -0.42 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 86.77 M Increased by +17.74% | -71.90 M Increased by +8.47% | Decreased by -82.87% Increased by +22.27% |
| Sep 30, 25 | 67.45 M Increased by +15.20% | -91.25 M Decreased by -9.23% | Decreased by -135.28% Increased by +5.18% |
| Jun 30, 25 | 59.95 M Increased by +92.73% | -111.66 M Decreased by -14.99% | Decreased by -186.25% Increased by +40.34% |
| Mar 31, 25 | 49.32 M Increased by +6.80 K% | -116.16 M Decreased by -2.82% | Decreased by -235.51% Increased by +98.51% |
| Dec 31, 24 | 73.69 M Increased by +15.19 K% | -78.56 M Increased by +32.50% | Decreased by -106.60% Increased by +99.56% |
| Sep 30, 24 | 58.55 M Increased by +12.38 K% | -83.54 M Increased by +26.56% | Decreased by -142.67% Increased by +99.41% |
| Jun 30, 24 | 31.11 M Increased by +12.97 K% | -97.10 M Increased by +8.85% | Decreased by -312.16% Increased by +99.30% |
| Mar 31, 24 | 715.00 K Increased by +N/A% | -112.98 M Decreased by -5.22% | Decreased by -15.80 K% Decreased by N/A% |